Pathogenic tau mutations

Details Pathogenic tau mutations Pathogenic tau mutations

1999-04-30

2002-11-05

Crouch, Deborah (Department: 1632)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S091200, C536S023500

Reexamination Certificate

active

06475723

ABSTRACT:

TECHNICAL FIELD
The invention relates to an isolated nucleic acid molecule that includes a tau gene sequence, wherein the tau gene sequence contains a mutation linked to a Tau pathology.
BACKGROUND OF THE INVENTION
Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) is characterized clinically by behavioral, cognitive, and motor disturbance. Historically, many cases of this disease have been described as Pick's disease. In the majority of families described to date, personality change is the presenting symptom, with initial behavioral changes accompanied by progressive cognitive impairment and sometimes parkinsonism. At autopsy, all patients with FTDP-17 display pronounced fronto-temporal atrophy and neuronal cell loss, gray and white matter gliosis, and superficial cortical spongiform changes. More variably, ballooned neurons, or Pick's cells, are present. In addition, most FTDP-17 cases show neuronal and/or glial inclusions that stain positively with antibodies raised against the microtubule associated protein Tau, although the Tau pathology varies considerably in both its quantity (or severity) and characteristics. Patients with FTDP-17 do not have Lewy bodies or, crucially, Pick bodies, which distinguishes them from classical Pick's disease cases. The disease is inherited as an autosomal dominant trait with age dependent penetrance. The age of onset can be highly variable but is usually between the ages of 45-65 years.
SUMMARY OF THE INVENTION
The invention is based on the discovery of mutations in the tau gene that are linked to Tau pathologies. Thus, the invention provides nucleic acid molecules that include such mutations, allowing animal models of neurodegenerative diseases to be developed. Identification of the mutations also provides methods for determining a diagnosis of neurodegenerative disease in a patient.
The invention features an isolated nucleic acid molecule including a tau gene sequence, wherein the molecule has a mutation linked to a Tau pathology. The nucleic acid molecule can be from about 15 nucleotides in length to full-length. The mutation can be located in an exon or in an intron. A mutation can be in exon
7
, exon
9
, exon
10
, or in exon
13
and in particular embodiments, at a region encoding amino acids
152
,
257
,
272
,
301
,
389
, or
406
. In one embodiment, the mutation at amino acid
152
is a change from an alanine to a threonine residue, the mutation at amino acid
257
is a change from a lysine to a threonine residue, and the mutation at amino acid
272
is a change from a glycine residue to a valine residue. The mutation at amino acid
301
can be a change from a proline residue to a leucine residue. The mutation at amino acid
389
can be a change from a glycine to an arginine residue. The mutation of amino acid
406
can be a change from an arginine to a tryptophan residue. An additional mutation can include deletion of amino acid
280
. The mutation also can be in a splice donor site region and, in a particular embodiment, can destabilize a stem-loop structure of the splice donor site region and can be in a region
13
-
16
nucleotides
3
′ of the exon
10
splice donor site.
The invention also features an isolated polypeptide encoded by a tau nucleic acid molecule of the invention. The polypeptides contain a mutation linked to a Tau pathology. Suitable mutations are described above.
The invention also features a transgenic non-human mammal including a nucleic acid construct. The nucleic acid construct includes a regulatory nucleic acid sequence operably linked to a nucleic acid sequence encoding a Tau polypeptide. Expression of the Tau polypeptide is linked to a Tau pathology in the transgenic non-human mammal. The transgenic non-human mammal can be a rodent, and in particular, a mouse. The regulatory nucleic acid sequence can be a brain-specific promoter. In one embodiment, the Tau polypeptide is human Tau polypeptide, and can be wild-type or can contain a mutation linked to a Tau pathology. The mutation can be, for example, at amino acid
152
,
257
,
272
,
280
,
301
,
389
, or
406
. In other embodiments, the transgenic non-human mammal also includes a nucleic acid construct that includes a regulatory sequence operably linked to a nucleic acid sequence encoding a human amyloid precursor protein or a human presenilin-1 protein.
The invention also relates to a method for determining a diagnosis, prognosis, or risk of neurodegenerative disease in a patient. The method includes detecting a tau gene mutation in genomic DNA of the patient, wherein the mutation is linked to a Tau pathology. Mutations that are linked to Tau pathologies are described above.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.


REFERENCES:
patent: 5958684 (1999-09-01), VanLeeuwen et al.
patent: WO 97/27296 (1997-07-01), None
patent: WO 97/48792 (1997-12-01), None
patent: WO 98/01549 (1998-01-01), None
patent: WO 98/17782 (1998-04-01), None
Conrad et al. Ann. Neurology 41(2):277-281, Feb. 1997.*
Ebert et al. Molecular Endocrinology 2(3):277-283, Mar. 1988.*
Hammer et al. Journal of Animal Science 63(1):269-278, Jul. 1986.*
Mullins et al. Journal of Clinical investigation 87(7):1557-1560, Apr. 1996.*
Wall et al. Journal of Dairy Science 80:2213-2224, Sep. 1997.*
Roks et al. Neuroscience Letters 277(2):137-139, Dec. 1999.*
Andreadis et al., “Structure and Novel Exons of the Human I Gene”,Biochemistry, 31(43)10626-10633 (1992).
Arrasate et al., “Polymerization of Tau Peptides into Fibrillar Structures. The Effect of FTDP-17 Mutations”,FEBS Letters, 446:199-202 (1999).
Baker et al., “Localization of Frontotemporal Dementia with Parkinsonism in an Australian Kindred to Chromosome 17q21-22”,Ann. Neurol., 42(5):794-798 (1997).
Dayanandan et al., “Mutations in Tau Reduce its Microtubule Binding Properties in Intact Cells and Affect its Phosphorylation”,FEBS Letters, 446:228-232 (1999).
Foster et al., “Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A Consensus Conference”,Ann. Neurol., 41(6):706-715 (Jun. 1997).
Froleich et al., “Mapping of a Disease Locus for Familial Rapidly Progressive Frontotemporal Dementia to Chromosome 17q12-21”,Amer. J. Med. Genet., 74:380-385 (1997).
Heutink et al., “Hereditary Frontotemporal Dementia is Linked to Chromosome 17q21-q22: A Genetic and Clinicopathological Study of Three Dutch Families”,Ann. Neurol., 41(2):150-159 (1997).
Hutton et al., “Association of Missense and 5′-Splice-Site Mutations intauwith the Inherited Dementia FTDP-17”,Nature, 393:702-705 (1998).
Ingelson et al., “Microtubule-Associated Protein Tau in Human Fibroblasts with the Swedish Alzheimer Mutation”,Neuroscience Letters, 220:9-12 (1996).
Jicha et al., “Sequence Requirements for Formation of Conformational Variants of Tau Similar to Those Found in Alzheimer's Disease”,J. Neurosci. Res., 55:713-723 (1999).
Leger et al., “Conversion of Serine to Asparate Imitates Phosphorylation Induced Charges in the Structure and Function of Microtubule-Associated Protein Tau”,J. Biol. Chem., 272(13):8441-8446 (1997).
Mirra et al., “Tau Pathology in a Family with Dementia and a P301L Mutation in Tau”,J. Neuropath. Exp. Neurol., 58(4):335-345 (1999).
Murrell et al., “Familial Multiple-System Tauopathy with Presenile Dementia is Localized to Chromosome 1

Affiliated with

Also associated with

Rating

Pathogenic tau mutations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pathogenic tau mutations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pathogenic tau mutations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2939744